Sepracor's (SEPR) Reports Results From LUNESTA(R) Study
Sepracor Inc. (Nasdaq: SEPR) announced the presentation of LUNESTA(R) brand eszopiclone Phase IV study data at the 21st European College of Neuropsychopharmacology (ECNP) Congress in Barcelona. The poster presentations reflected results from a 12-week, double-blind, randomized safety and efficacy study of 388 elderly patients (65-85 years of age) who were administered either LUNESTA 2 mg or placebo nightly. Upon conclusion of the 12-week, double-blind treatment period, all patients received single-blind placebo for two weeks to assess rebound and withdrawal effects. This two-week, single-blind period was then followed by an additional two-week evaluation period in which patients received neither LUNESTA nor placebo in order to assess the durability of the response.
Patients administered LUNESTA reported significant improvements from baseline in key measures of daytime function versus the placebo group when averaged over the 12-week, double-blind treatment period.
Patients administered LUNESTA reported significant improvements from baseline in key measures of daytime function versus the placebo group when averaged over the 12-week, double-blind treatment period.
You May Also Be Interested In
- Vertex Pharmaceuticals (VRTX) Gets Positive Opinion from CHMP for KALYDECO
- Syngenta (SYT) settles atrazine litigation; will pay $105M in deal
- Catalyst Pharmaceutical (CPRX) Reports Encouraging Data from CPP-115 Phase Ia
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
